









Markets
/
Stocks
/
nasdaq-nams
/

NewAmsterdam Pharma Company NV

NAMS

36.925USD

-0.075-0.20%

Market hours （ET）Quotes delayed by 15 min

4.15BMarket Cap

LossP/E TTM



NewAmsterdam Pharma Company NV

36.925

-0.075-0.20%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of NewAmsterdam Pharma Company NV

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

NewAmsterdam Pharma Company NV's Score

Industry at a Glance

Industry Ranking

3 / 407

Overall Ranking

32 / 4617

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 15 analysts

Buy

Current Rating

43.000

Target Price

+13.31%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

NewAmsterdam Pharma Company NV Highlights

StrengthsRisks

NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.

Growing

The company is in a growing phase, with the latest annual income totaling USD 45.56M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 45.56M.

Undervalued

The company’s latest PE is -23.18, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 119.62M shares, increasing 2.53% quarter-over-quarter.

Held by Stanley Druckenmiller

Star Investor Stanley Druckenmiller holds 832.17K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 9.29, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 19.14M, representing a year-over-year increase of 740.06%, while its net profit experienced a year-over-year increase of 55.48%.

Score

Industry at a Glance

Previous score

9.29

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.54

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.31

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.58

Key Metrics

Free cash flow

No Data

NewAmsterdam Pharma Company NV's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 6.93, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -23.18, which is -91.12% below the recent high of -2.06 and -9.32% above the recent low of -25.35.

Score

Industry at a Glance

Previous score

6.93

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 3/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 8.80, which is higher than the Biotechnology & Medical Research industry's average of 8.01. The average price target for NewAmsterdam Pharma Company NV is 44.00, with a high of 52.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

8.77

Change

0.03

Support & Resistance

No Data

Analyst Rating

Based on 15 analysts

Buy

Current Rating

43.000

Target Price

+16.22%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

NewAmsterdam Pharma Company NV

NAMS

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 8.94, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 41.82 and the support level at 31.84, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.15

Change

-0.21

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.512

Neutral

RSI(14)

59.114

Neutral

STOCH(KDJ)(9,3,3)

63.479

Neutral

ATR(14)

2.319

Low Volatility

CCI(14)

17.648

Neutral

Williams %R

62.649

Sell

TRIX(12,20)

0.936

Sell

StochRSI(14)

3.941

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

37.129

Sell

MA10

36.517

Buy

MA20

36.314

Buy

MA50

30.424

Buy

MA100

26.093

Buy

MA200

22.991

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 106.21%, representing a quarter-over-quarter decrease of 7.54%. The largest institutional shareholder is Andreas Halvorsen, holding a total of 6.98M shares, representing 6.20% of shares outstanding, with 4.05% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Frazier Life Sciences Management, L.P.

16.63M

+0.11%

Bain Capital Life Sciences Investors, LLC

10.72M

RA Capital Management, LP

10.14M

Forbion Capital Partners

9.32M

-11.93%

Capital World Investors

8.39M

+23.37%

Viking Global Investors LP

Star Investors

6.98M

Deerfield Management Company, L.P.

5.12M

+24.66%

Jennison Associates LLC

2.95M

-25.79%

Wellington Management Company, LLP

3.32M

-6.18%

Adage Capital Management, L.P.

3.01M

+54.46%

Risk Assessment

Currency: USD Updated: 2025-11-03

The company’s current risk assessment score is 5.79, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.06. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.